Why most PET of lung and head-and-neck cancer will be PET/CT.
Why most PET of lung and head-and-neck cancer will be PET/CT.
复制标题
为什么大多数肺癌和头颈癌的 PET 都是 PET/CT。
DOI：
--
复制
发表时间：
2004
影响因子：
9.3
通讯作者：
H. Steinert
中科院分区：
文献类型：
--
作者：
G. Goerres;G. V. von Schulthess;H. Steinert
我们和其他机构使用PET/CT成像肺部和头颈癌的经验表明，这种新模式比单独使用PET具有更高的特异性和敏感性，在某些情况下甚至与PET和CT并排观察相比。最大的经验存在于非小细胞肺癌（NSCLC），其中PET/CT在T和N分期方面优于PET和CT。M分期的优越性还有待证明。CT造影剂增强可能仅在存在实质性纵隔肿瘤成分时才需要。在这种情况下，从血管结构中勾画肿瘤是相关的。在耳鼻喉肿瘤中，PET/CT也优于PET，可能也优于PET和CT并排观察。早期的信息表明，分级可能不需要造影剂增强，但可用的数据仍然有限。在这两种情况下，值得注意的是，在许多患者中，PET/CT发现第二异时性肿瘤，主要局限于胃肠道。
Experience in our and other institutions with PET/CT imaging of lung and head and neck cancers has shown that this new modality has higher specificity and sensitivity than PET alone and in certain settings even when compared to PET and CT viewed side by side. The largest experience exists with non-small cell lung cancer (NSCLC), in which it has been demonstrated that PET/CT is superior to PET and CT in T and in N staging. Superiority in M staging has yet to be demonstrated. CT contrast media enhancement is probably only necessary when a substantial mediastinal tumor component is present. In such cases, delineation of tumor from vascular structures is relevant. In ENT tumors, PET/CT also appears to be superior to PET, and probably also to PET and CT viewed side by side. Early information suggests that contrast media enhancement for staging may not be required, but the data available is still limited. In both settings, it is interesting to note that in a number of patients, second metachronous tumors are discovered with PET/CT, mainly localized in the GI tract.